Formulary
Reslizumab: Indications, Dosing, Side Effects and Interactions
Reslizumab is a humanised monoclonal antibody that interferes with interleukin-5 receptor binding, thereby reducing the survival and activity of eosinophils.
MedNext Academy | 3 min read
Reslizumab: Indications, Dosing, Side Effects and Interactions
Reslizumab is a humanised monoclonal antibody that interferes with interleukin-5 receptor binding, thereby reducing the survival and activity of eosinophils.
Drug action
Reslizumab is a humanised monoclonal antibody that interferes with interleukin-5 receptor binding, thereby reducing the survival and activity of eosinophils.
Indications and dose
**Severe eosinophilic asthma (adjunctive therapy when inadequately controlled by high-dose corticosteroids plus another standard treatment) (specialist use only)**
- **Adult** (By Intravenous Infusion): (consult product literature).
Cautions
Hypersensitivity reactions; pre-existing helminth infection Cautions, further information Helminth infection Manufacturer advises to treat pre-existing helminth infections before starting reslizumab-consider temporarily discontinuing reslizumab if patient becomes infected during therapy and does not respond to anti-helminth treatment. Hypersensitivity reactions Serious hypersensitivity reactions, including life-threatening anaphylaxis, can occur and manufacturer advises to monitor closely during treatment and for at least 20 minutes after completion of infusion; in the event of a hypersensitivity reaction, treatment should be permanently discontinued.
Side effects
Anaphylactic reaction; myalgia Frequency not known Secondary malignancy
Interactions
**Other interactions (5):**
- No formal clinical interaction studies have been performed with reslizumab.
- Results of population pharmacokinetic analysis confirm that concomitant use of either leukotriene antagonists or systemic corticosteroids does not affect the pharmacokinetics of reslizumab (see...
- Reslizumab has not been studied in patients concurrently taking immunosuppressant medicinal products other than oral corticosteroids (OCS); therefore, the safety and efficacy profile of reslizumab...
- Reslizumab has not been studied in patients receiving live vaccines.
- No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving reslizumab or the response to new immunisations in patients receiving...
Pregnancy
Manufacturer advises avoid-limited information available.
Breast feeding
Manufacturer advises avoid during first few days after birth-risk of transfer of antibodies to infant cannot be excluded; present in milk in animal studies.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Reslizumab in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

